BMYCelgeneFinished
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 149 (final count)
- Started
- Dec 13, 2017
- Main results expected
- Dec 20, 2023
- Fully finished
- Dec 20, 2023
- Results posted
- May 23, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: From first dose to 24 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03361748 · record last updated 2025-05-23 · checked 2026-11-09 15:47 UTC